Heska (NASDAQ:HSKA) will be announcing its earnings results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Heska has set its FY 2020
Pre-Market guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.44). The company had revenue of $30.65 million for the quarter, compared to analysts’ expectations of $33.47 million. Heska had a negative net margin of 5.99% and a negative return on equity of 1.04%. On average, analysts expect Heska to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
HSKA stock opened at $96.22 on Friday. The company has a quick ratio of 9.89, a current ratio of 11.21 and a debt-to-equity ratio of 0.19. The company has a market cap of $903.51 million, a price-to-earnings ratio of -96.22 and a beta of 1.72. The business has a fifty day simple moving average of $92.22 and a 200-day simple moving average of $85.11. Heska has a 52 week low of $50.00 and a 52 week high of $110.90.
In related news, CEO Kevin S. Wilson sold 10,000 shares of Heska stock in a transaction on Friday, June 5th. The shares were sold at an average price of $91.00, for a total transaction of $910,000.00. Following the sale, the chief executive officer now owns 82,955 shares of the company’s stock, valued at approximately $7,548,905. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin S. Wilson sold 9,707 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $89.00, for a total transaction of $863,923.00. Following the completion of the transaction, the chief executive officer now owns 82,955 shares in the company, valued at approximately $7,382,995. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,941 shares of company stock worth $2,741,842. Corporate insiders own 11.70% of the company’s stock.
Several equities research analysts have commented on the company. ValuEngine lowered Heska from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Alliance Global Partners increased their target price on shares of Heska from $78.00 to $90.00 in a research report on Friday, May 8th. Zacks Investment Research cut shares of Heska from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. BidaskClub upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 25th. Finally, Piper Sandler cut their target price on shares of Heska from $107.00 to $87.00 in a research note on Monday, May 25th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $81.67.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Recommended Story: What are the economic characteristics of a bear market?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.